A study published in 2023 by Adachi et al. emphasized the significance of altering gene expression in cancer cells to trigger the epithelial-to-mesenchymal transition (EMT) when KRAS G12C is inhibited. Through extensive in vitro experiments, researchers discovered that KRAS G12C inhibitors activated yes-associated protein (YAP). This evidence concerns the gene KRAS and cancer.